Drug intelligence / Profile preview

duloxetine + vortioxetine

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Duloxetine + vortioxetine is a combination of two antidepressant medications, each with distinct but complementary mechanisms of action. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the brain by inhibiting their reuptake at synaptic terminals. Vortioxetine is classified as a multimodal antidepressant; it acts primarily as a serotonin reuptake inhibitor and also modulates several serotonin receptors, functioning as an agonist or antagonist at different subtypes. Both drugs are approved for the treatment of major depressive disorder (MDD), and duloxetine is also indicated for generalized anxiety disorder, neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. The combination may be considered in select cases where monotherapy has been insufficient; however, co-administration significantly increases the risk of serotonin syndrome due to additive serotonergic effects[1]. This combination should only be used under close medical supervision.

02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))SERT (Sodium-dependent serotonin transporter)HTR3A (5-hydroxytryptamine receptor 3A)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR7 (5-hydroxytryptamine receptor 7)HTR1D (5-hydroxytryptamine receptor 1D)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on duloxetine + vortioxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on duloxetine + vortioxetine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call